Skip to main content

Advertisement

SpringerLink
Log in

VEGF and TSP1 levels correlate with prognosis in advanced non-small cell lung cancer

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Purpose

There is a need for biomarkers that may help in selecting the most effective anticancer treatments for each patient. We have investigated the prognostic value of a set of angiogenesis, inflammation and coagulation markers in patients treated for advanced non-small cell lung cancer.

Patients and methods

Peripheral blood samples were obtained from 60 patients before first line platinum-based chemotherapy ± bevacizumab, and after the third cycle of treatment. Blood samples from 60 healthy volunteers were also obtained as controls. Angiogenesis, inflammation and coagulation markers vascular endothelial growth factor (VEGF), their soluble receptors 1 (VEGFR1) and 2 (VEGFR2), thrombospondin-1 (TSP-1), interleukin-6 (IL6), sialic acid (SA) and tissue factor (TF) were quantified by ELISA.

Results

Except for TSP-1, pre- and post-treatment levels of all markers were higher in patients than in controls (p < 0.05). There was a positive and significant correlation between VEGF and VEGFR2 before treatment. VEGF also correlated with inflammatory markers IL-6 and SA. Moreover, there was a positive and significant correlation between levels of VEGFR1 and TF. Decreased levels of TSP-1 and increased levels of VEGF were associated with shorter survival. Bevacizumab significantly modified angiogenesis parameters and caused a decrease of VEGF and an increase of TSP-1.

Conclusion

Angiogenesis, inflammation and coagulation markers were increased in NSCLC patients. Increased levels of VEGF and low levels of TSP-1 correlated with a poor prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Herbst R, Onn A, Sandler A. Angiogenesis and lung cancer:prognostic and therapeutic implications. J Clin Oncol. 2005;23:3243–56.

    Article  PubMed  CAS  Google Scholar 

  2. Hicklin DJ, Ellis LM. Role of the vascular endotelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011–27.

    Article  PubMed  CAS  Google Scholar 

  3. Delmotte P, Martin B, Paesmans M, Berghmans T, Mascaux C, Meert AP, et al. VEGF and survival of patients with lung cancer: a systematic literature review and meta-analysis. Rev Mal Respir. 2002;19:577–84.

    PubMed  CAS  Google Scholar 

  4. Dudek AZ, Mahaseth H. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Cancer Invest. 2005;23:193–200.

    Article  PubMed  CAS  Google Scholar 

  5. Lopez-Dee Z, Pidcock K, Gutierrez LS. Thrombospondin-1: multiple paths to inflammation. Mediat Inflamm. 2011;2011:296069.

    Article  Google Scholar 

  6. Papadaki C, Tsaroucha E, Kaklamanis L, Lagoudaki E, Trypaki M, Tryfonidis K, et al. Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer. Br J Cancer. 2011;104:316–23.

    Article  PubMed  CAS  Google Scholar 

  7. Anderson JC, McFarland BC, Gladson CL. New molecular targets in angiogenic vessels of glioblastoma tumours. Expert Rev Mol Med. 2008;10:e23. doi:10.1017/S1462399408000768.

    Article  PubMed  Google Scholar 

  8. Yamaji H, Iizasa T, Koh E, Suzuki M, Otsuji M, Chang H, et al. Correlation between interleukin 6 production and tumor proliferation in non-small cell lung cancer. Cancer Immunol Immunother. 2004;53:786–92.

    Article  PubMed  CAS  Google Scholar 

  9. Miyagi T, Wada T, Yamaguchi K, Shiozaki K, Sato I, Kakugawa Y, et al. Human sialidase as a cancer marker. Proteomics. 2008;8:3303–11.

    Article  PubMed  CAS  Google Scholar 

  10. Celen O, Yildirim E, Ozen N, Sonmez C. Predictive value of relative changes in serum total sialic acid level for response to neoadjuvant chemotherapy in patients with locally advanced breast carcinoma. Neoplasma. 2006;53:347–51.

    PubMed  CAS  Google Scholar 

  11. Ruf W, Disse J, Carneiro-Lobo TC, Yokota N, Schaffner F. Tissue factor and cell signalling in cancer progression and thrombosis. J Thromb Haemost. 2011;1:306–15.

    Article  Google Scholar 

  12. Goldin-Lang P, Tran QV, Fichtner I, Eisenreich A, Antoniak S, Schulze K, et al. Tissue factor expression pattern in human non-small cell lung cancer tissues indicate increased blood thrombogenicity and tumor metastasis. Oncol Rep. 2008;20:123–8.

    PubMed  CAS  Google Scholar 

  13. Koomägi R, Volm M. Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis. Int J Cancer. 1998;79:19–22.

    Article  PubMed  Google Scholar 

  14. Regina S, Rollin J, Bléchet C, Iochmann S, Reverdiau P, Gruel Y. Tissue factor expression in non-small cell lung cancer: relationship with vascular endothelial growth factor expression, microvascular density, and K-ras mutation. J Thorac Oncol. 2008;3:689–97.

    Article  PubMed  Google Scholar 

  15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors (RECIST Guidelines). J Natl Cancer Inst. 2000;92:205–16.

    Article  PubMed  CAS  Google Scholar 

  16. Martínez-Sales V, Vila V, Ferrando M, Reganon E. Atorvastatin neutralizes the up-regulation of thrombospondin-1 induced by thrombin in human umbilical vein endothelial cells. Endothelium. 2007;14:233–8.

    PubMed  Google Scholar 

  17. Jantus-Lewintre E, Sanmartín E, Sirera R, Blasco A, Sanchez JJ, Tarón M, et al. Combined VEGF and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC. Lung Cancer. 2011;74:326–31.

    Article  PubMed  Google Scholar 

  18. Pajares MJ, Agorreta J, Larrayoz M, Vesin A, Ezponda T, Zudaire I, et al. Expression of tumor-derived vascular endotelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung. J Clin Oncol. 2012;30:1129–36.

    Article  PubMed  Google Scholar 

  19. Heist RS, Zhai R, Liu G, Zhou W, Lin X, Su L, et al. VEGF polymorphisms and survival in early-stage non small cell lung cancer. J Clin Oncol. 2008;26:856–62.

    Article  PubMed  CAS  Google Scholar 

  20. Angelo L, Kurzrock R. Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res. 2007;13:2825–30.

    Article  PubMed  CAS  Google Scholar 

  21. Kita H, Shiraishi Y, Watanabe K, Suda K, Ohtsuka K, Koshiishi Y, et al. Does postoperative serum interleukin-6 influence early recurrence after curative pulmonary resection of lung cancer? Ann Thorac Cardiovasc Surg. 2011;17:454–60.

    Article  PubMed  Google Scholar 

  22. Koh E, Lizasa T, Yamaji H. Significance of the correlation between the expression of interleukin 6 and clinical features in patients with non-small cell lung cancer. Int J Surg Pathol. 2012;20:233–9.

    Article  PubMed  CAS  Google Scholar 

  23. Chang CH, Hsiao CF, Yeh YM, Chang GC, Tsai YH, Chen YM, et al. Circulating interleukin-6 level is a prognostic marker for survival in advanced non small cell lung cancer patients treated with chemotherapy. Int J Cancer; 2012 doi:10.1002/ijc.27892. [Epub ahead of print].

  24. Zhou B, Liu J, Wang ZM, Xi T. C-reactive protein, interleukin 6 and lung cancer risk: a meta-analysis. PLoS ONE. 2012;7:e43075.

    Article  PubMed  CAS  Google Scholar 

  25. Reynés G, Vila V, Martín M, Parada A, Fleitas T, Reganon E, et al. Circulating markers of angiogenesis, inflammation, and coagulation in patients with glioblastoma. J Neurooncol. 2011;102:35–41.

    Article  PubMed  Google Scholar 

  26. Sawhney H, Kumar CA. Correlation of serum biomarkers (TSA & LSA) and epithelial dysplasia in early diagnosis of oral precancer and oral cancer. Cancer Biomark. 2012;10:43–9.

    Google Scholar 

  27. Almaraz RT, Tian Y, Bhattarcharya R, Tan E, Chen SH, Dallas MR, et al. Metabolic flux increases glycoprotein sialylation: implications for cell adhesion and cancer metastasis. Mol Cell Proteomics 2012; 11:M112.017558. doi:10.1074/mcp.M112.017558.

  28. Versteeg HH, Schaffner F, Kerver M, Petersen HH, Ahamed J, Felding-Habermann B, et al. Inhibition of tissue factor signaling suppresses tumor growth. Blood. 2008;11:190–9.

    Article  Google Scholar 

  29. Corrales-Rodriguez L, Blais N. Lung cancer associated venous thromboembolic disease: a comprehensive review. Lung Cancer. 2012;75:1–8.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported in part by Fundación para la investigación, Hospital Universitario La Fe-Bancaja.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Hospital Clínico Universitario de Valencia, Avda Blasco Ibañez 17, 46010, Valencia, Spain

    T. Fleitas

  2. Research Center, Hospital Universitario y Politécnico La Fe, Avda Campanar 21, 46009, Valencia, Spain

    V. Martínez-Sales, V. Vila, E. Reganon & D. Mesado

  3. Department of Medical Oncology, Hospital Universitario y Politécnico La Fe, Avda Campanar 21, 46009, Valencia, Spain

    M. Martín, J. Gómez-Codina, J. Montalar & G. Reynés

Authors
  1. T. Fleitas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. Martínez-Sales
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V. Vila
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Reganon
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. Mesado
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Martín
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. Gómez-Codina
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. Montalar
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G. Reynés
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Fleitas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fleitas, T., Martínez-Sales, V., Vila, V. et al. VEGF and TSP1 levels correlate with prognosis in advanced non-small cell lung cancer. Clin Transl Oncol 15, 897–902 (2013). https://doi.org/10.1007/s12094-013-1020-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-013-1020-6

Keywords

Search

Navigation